Increasing reports of poor quality of medicines manufactured in India, whether as exports or for domestic consumption, are a matter of great concern. But this crisis should not become an excuse for strengthening corporate monopoly and excessive centralization. In this conversation, we discuss the why and how of designing a regulatory regime in India, that can guarantee quality medicines without any compromise to affordability or public health, not only for India, but for the entire third world.
19th Ave New York, NY 95822, USA
